Browsing by keyword "Nerve Tissue"
Now showing items 1-2 of 2
-
Heterogeneous nuclear ribonucleoprotein E3 modestly activates splicing of tau exon 10 via its proximal downstream intron, a hotspot for frontotemporal dementia mutationsThe microtubule-associated protein tau is important to normal neuronal activity in the mammalian nervous system. Aggregated tau is the major component of neurofibrillary tangles (NFTs), structures present in the brains of people affected by neurodegenerative diseases called tauopathies. Tauopathies include Alzheimer's disease (AD), frontotemporal dementia with Parkinsonism (FTDP) and the early-onset dementia observed in Down syndrome (DS; trisomy 21). Splicing misregulation of adult-specific exon 10 results in expression of abnormal ratios of tau isoforms, leading to FTDP. Positions +3 to +19 of the intron downstream of exon 10 define a hotspot: Point mutations in it result in tauopathies. All these mutations increase exon 10 inclusion except for mutation +19, which almost entirely excludes exon 10. To investigate the tau connection between DS and AD, we examined splicing factors located on chromosome 21 for their effect on tau exon 10. By co-transfections, co-immunoprecipitations and RNAi constructs, we discovered that one of them, hnRNPE3 (PCBP3), modestly activates splicing of exon 10 by interacting with its proximal downstream intron around position +19. These results, coupled with the developmental profile of hnRNPE3, suggest a pathogenic role for splicing factors on chromosome 21 in neurodegenerative diseases with tangles and create a connection between tau splicing and the early-onset dementia of Down syndrome.
-
Novel drug delivery systems: opportunities and caveatsProgrammed infusion pumps, polymers and neural transplants provide the capability of delivering a variety of agents to specific locations in the central nervous system. If a necessary or therapeutically useful substance cannot otherwise penetrate the blood-brain barrier, or must be delivered to a precise location in the CNS, these strategies may be of value in neurologic disease. The possibility of transplanting functioning tissue into the brain raises the hope of providing "new parts for old." For drugs that can penetrate the blood-brain barrier, and do not require a single precise anatomic site of action, systemic administration remains the "gold standard." The role of these novel drug delivery systems in treatment of Alzheimer's disease is as yet unclear.